ストックスクリーナーアプリを入手
83.81
1.21%
-1.01
前日終値:
$84.82
開ける：
$85.01
24時間の取引高:
649.10K
Relative Volume:
0.16
時価総額：
$34.03B
収益：
$4.15B
当期純損益:
$535.20M
株価収益率:
62.54
EPS:
1.34
ネットキャッシュフロー:
$575.20M
1週間 パフォーマンス:
-2.12%
1か月 パフォーマンス:
-1.04%
6か月 パフォーマンス:
+4.13%
1年 パフォーマンス:
-28.32%
1日の値動き範囲:
$83.63
$85.49
1週間の範囲:
$83.63
$87.91
52週間の値動き範囲:
$57.52
$118.80
Dexcom Inc Stock (DXCM) Company Profile
DXCM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
83.86 | 34.03B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
134.53 | 232.63B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
99.61 | 152.53B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.86 | 145.61B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.22 | 109.66B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.88 | 45.59B | 5.54B | 4.18B | 623.10M | 7.00 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-30 | 開始されました | Goldman | Buy |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-02-03 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 開始されました | Redburn Atlantic | Neutral |
| 2024-03-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-04-17 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2023-01-26 | 開始されました | Wolfe Research | Outperform |
| 2022-10-18 | 開始されました | Barclays | Equal Weight |
| 2022-10-12 | 開始されました | Jefferies | Buy |
| 2022-07-15 | 開始されました | Bernstein | Outperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-02-03 | アップグレード | BTIG Research | Neutral → Buy |
| 2022-01-19 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-07-21 | 再開されました | Cowen | Outperform |
| 2021-05-28 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Overweight |
| 2021-01-06 | アップグレード | UBS | Neutral → Buy |
| 2020-10-02 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 繰り返されました | Piper Sandler | Overweight |
| 2020-05-14 | 開始されました | Wells Fargo | Equal Weight |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2019-11-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-11-07 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-10-23 | 開始されました | Stifel | Buy |
| 2018-11-28 | 開始されました | UBS | Neutral |
| 2018-10-19 | アップグレード | Goldman | Sell → Neutral |
| 2018-09-12 | アップグレード | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-07-02 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 開始されました | BofA/Merrill | Buy |
| 2018-05-03 | 繰り返されました | Canaccord Genuity | Buy |
| 2018-04-04 | 開始されました | Goldman | Sell |
| 2018-04-04 | 開始されました | Guggenheim | Neutral |
| 2018-03-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | ダウングレード | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 繰り返されました | Wedbush | Outperform |
すべてを表示
Dexcom Inc (DXCM) 最新ニュース
Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders - Business Wire
Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7 - MassDevice
Insulet Corporation's Omnipod 5 App for Iphone with Dexcom G7 Integration Now Available to All U.S. Users - marketscreener.com
Insulet Releases Omnipod 5 App for iPhone with Dexcom G7 CGM in U.S. - Medical Product Outsourcing
Insulet's Omnipod® 5 App For iPhone With Dexcom G7 Integration Now Available To All US Users - marketscreener.com
Insulet (PODD) Omnipod 5 App Now Compatible with Dexcom G7 on iPhone | PODD Stock News - GuruFocus
Insulet's Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users | PODD Stock News - GuruFocus
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users - Business Wire
DexCom (NASDAQ:DXCM) Stock Rating Upgraded by Wall Street Zen - Defense World
DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders - GlobeNewswire
BGM and CGM Market is Set to Experience a Revolutionary Growth | Abbott Laboratories , Dexcom, Medtronic PLC - openPR.com
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Benzinga
Should You Be Excited About DexCom, Inc.'s (NASDAQ:DXCM) 24% Return On Equity? - simplywall.st
Goldman Sachs Initiates Coverage of DexCom (XTRA:DC4) with Buy Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of DexCom (BIT:1DXCM) with Buy Recommendation - Nasdaq
DexCom (NASDAQ:DXCM) Now Covered by Analysts at The Goldman Sachs Group - Defense World
Goldman Sachs Initiates Coverage of DexCom (DXCM) with Buy Recommendation - Nasdaq
Goldman Sachs Initiates Coverage of DexCom (DXCM) With Buy Rating - MSN
Forecasting The Future: 7 Analyst Projections For DexCom - Benzinga
DexCom, Inc. (NASDAQ:DXCM) Q2 2024 Earnings Call Transcript - MSN
Jefferies Adjusts Price Target on DexCom to $110 From $105, Maintains Buy Rating - marketscreener.com
Goldman Sachs Initiates DexCom at Buy With $104 Price Target - marketscreener.com
DexCom (DXCM) Receives Positive Coverage with Growth Potential | - GuruFocus
DexCom (DXCM) Receives Positive Coverage with Growth Potential | DXCM Stock News - GuruFocus
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - The Globe and Mail
DexCom, Inc. (DXCM) Stock Analysis: 15.97% Potential Upside Amid Robust Analyst Support - DirectorsTalk Interviews
DexCom’s SWOT analysis: CGM leader faces supply challenges amid growth - Investing.com
DexCom: Non-Insulin Type 2 Diabetes Market Penetration Be A Breakthrough Move? - Smartkarma
An Intrinsic Calculation For DexCom, Inc. (NASDAQ:DXCM) Suggests It's 27% Undervalued - Yahoo Finance
Blood Glucose Monitoring (BGM) Devices Market Report 2025: Hospitals Lead in Blood Glucose Monitoring Device Usage, Home Care Grows Fastest - GlobeNewswire Inc.
DexCom (DXCM) Maintains Buy Rating as Price Target Raised to USD 102 | DXCM Stock News - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Sto - GuruFocus
Citi Increases Price Target for DexCom (DXCM) to $102 | DXCM Stock News - GuruFocus
Diabetic Care Device Market Set for Significant Growth with 10.1% CAGR - GlobeNewswire Inc.
Dexcom (DXCM) Gets a Buy from Wells Fargo - The Globe and Mail
DexCom adds Renée Galá to Board of Directors By Investing.com - Investing.com Nigeria
3 Big Reasons to Love DexCom (DXCM) - Yahoo Finance
The End Of The Diabetes Industry?Eli Lilly (NYSE:LLY), DexCom (NASDAQ:DXCM) - Benzinga
3 Prominent Stocks Estimated To Be Trading Below Intrinsic Value By Up To 46.9% - simplywall.st
FDA Approves DexCom G4 Platinum Professional Continuous Glucose Monitoring System - Medical Product Outsourcing
Can DexCom, Inc. (NASDAQ:DXCM) Maintain Its Strong Returns? - Yahoo Finance
Here's Why You Should Add DexCom Stock to Your Portfolio Now - MSN
Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products - MedTech Dive
Is DexCom, Inc. (NASDAQ:DXCM) Trading At A 24% Discount? - simplywall.st
Do Wall Street Analysts Like DexCom Stock? - Nasdaq
DXCM Q1 Earnings Call: Coverage Expansion and Product Pipeline Shape 2025 Outlook - Yahoo Finance
Dexcom Beats Investor Claims Over Sales Growth Potential for Now - Bloomberg Law News
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil - TradingView
Dexcom Beats Investor Claims Over Growth Potential for Now (1) - Bloomberg Law News
DexCom, Inc. (DXCM) Announces Leadership Promotion: Jacob S. Lea - GuruFocus
Dexcom Inc (DXCM) 財務データ
収益
当期純利益
現金流量
EPS
Dexcom Inc (DXCM) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Stern Sadie | EVP, Chief HR Officer |
May 27 '25 |
Sale |
85.11 |
6,184 |
526,318 |
109,621 |
| Brown Michael Jon | EVP, Chief Legal Officer |
May 23 '25 |
Sale |
84.28 |
10,000 |
842,849 |
95,602 |
0.16%
0.08%
大文字化:
|
ボリューム (24 時間):